Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis

Isaacs, 2002, Focus on prostate cancer, Cancer Cell, 2, 113, 10.1016/S1535-6108(02)00103-4 Abate-Shen, 2000, Molecular genetics of prostate cancer, Genes Dev, 14, 2410, 10.1101/gad.819500 Tomlins, 2005, Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer, Science, 310, 644, 10.1126/science.1117679 Dang, 2006, The c-Myc target gene network, Semin Cancer Biol, 16, 253, 10.1016/j.semcancer.2006.07.014 Knoepfler, 2008, Why Myc? An unexpected ingredient in the stem cell cocktail, Cell Stem Cell, 2, 18, 10.1016/j.stem.2007.12.004 Nesbit, 1999, MYC oncogenes and human neoplastic disease, Oncogene, 18, 3004, 10.1038/sj.onc.1202746 Jenkins, 1997, Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization, Cancer Res, 57, 524 Sato, 1999, Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma, J Natl Cancer Inst, 91, 1574, 10.1093/jnci/91.18.1574 Qian, 1997, Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization, Mod Pathol, 10, 1113 Bethel, 2006, Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia and adenocarcinoma: association with Gleason score and chromosome 8p deletion, Cancer Res, 66, 10683, 10.1158/0008-5472.CAN-06-0963 Nupponen, 1999, Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer, Am J Pathol, 154, 1777, 10.1016/S0002-9440(10)65433-8 Reiter, 2000, Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer, Genes Chromosomes Cancer, 27, 95, 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3 Saramaki, 2001, Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer, Am J Pathol, 159, 2089, 10.1016/S0002-9440(10)63060-X Tsuchiya, 2002, Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer, Am J Pathol, 160, 1799, 10.1016/S0002-9440(10)61126-1 Porkka, 2004, RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer, Genes Chromosomes Cancer, 39, 1, 10.1002/gcc.10289 Fleming, 1986, Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia, Cancer Res, 46, 1535 Buttyan, 1987, Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers, Prostate, 11, 327, 10.1002/pros.2990110405 Meng, 2002, Molecular genetics of prostate cancer, 42 Zhang, 2000, Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein, Prostate, 43, 278, 10.1002/1097-0045(20000601)43:4<278::AID-PROS7>3.0.CO;2-4 Ellwood-Yen, 2003, Myc-driven murine prostate cancer shares molecular features with human prostate tumors, Cancer Cell, 4, 223, 10.1016/S1535-6108(03)00197-1 Williams, 2005, Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype, Prostate, 63, 369, 10.1002/pros.20200 Sears, 2004, The life cycle of C-myc: from synthesis to degradation, Cell Cycle, 3, 1133, 10.4161/cc.3.9.1145 Adhikary, 2005, Transcriptional regulation and transformation by Myc proteins, Nat Rev Mol Cell Biol, 6, 635, 10.1038/nrm1703 Yang, 2005, Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression, Cancer, 103, 1186, 10.1002/cncr.20905 Fox, 1993, p53 and c-myc expression in stage A1 prostatic adenocarcinoma: useful prognostic determinants?, J Urol, 150, 490, 10.1016/S0022-5347(17)35533-7 Persson, 1984, Nuclear localization and DNA binding properties of a protein expressed by human c-myc oncogene, Science, 225, 718, 10.1126/science.6463648 Stone, 1987, Definition of regions in human c-myc that are involved in transformation and nuclear localization, Mol Cell Biol, 7, 1697 Smith, 2004, c-Myc localization within the nucleus: evidence for association with the PML nuclear body, J Cell Biochem, 93, 1282, 10.1002/jcb.20273 Faith, 2004, Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays, The Prostate, 61, 215, 10.1002/pros.20095 Schuhmacher, 1999, Control of cell growth by c-Myc in the absence of cell division, Curr Biol, 9, 1255, 10.1016/S0960-9822(99)80507-7 Cornish, 2007 Dunn, 2006, A novel role of myosin VI in human prostate cancer, Am J Pathol, 169, 1843, 10.2353/ajpath.2006.060316 Rhodes, 2007, Oncomine 3.0: genes, pathways, and networks in a collection of 18 000 cancer gene expression profiles, Neoplasia, 9, 166, 10.1593/neo.07112 Lapointe, 2004, Gene expression profiling identifies clinically relevant subtypes of prostate cancer, Proc Natl Acad Sci USA, 101, 811, 10.1073/pnas.0304146101 Dhanasekaran, 2005, Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty, FASEB J, 19, 243, 10.1096/fj.04-2415fje Varambally, 2005, Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression, Cancer Cell, 8, 393, 10.1016/j.ccr.2005.10.001 Tomlins, 2007, Integrative molecular concept modeling of prostate cancer progression, Nat Genet, 39, 41, 10.1038/ng1935 Yu, 2004, Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy, J Clin Oncol, 22, 2790, 10.1200/JCO.2004.05.158 Alitalo, 1983, Identification of nuclear proteins encoded by viral and cellular myc oncogenes, Nature, 306, 274, 10.1038/306274a0 Gao, 2007, HIF-dependent antitumorigenic effect of antioxidants in vivo, Cancer Cell, 12, 230, 10.1016/j.ccr.2007.08.004 Goga, 2007, Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC, Nat Med, 13, 820, 10.1038/nm1606 Krivtsov, 2006, Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9, Nature, 442, 818, 10.1038/nature04980 van Leenders, 2000, Demonstration of intermediate cells during human prostate epithelial differentiation in situin vitro using triple-staining confocal scanning microscopy, Lab Invest, 80, 1251, 10.1038/labinvest.3780133 Litvinov, 2003, Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?, J Clin Endocrinol Metab, 88, 2972, 10.1210/jc.2002-022038 De Marzo, 1998, Stem cell features of benign and malignant prostate epithelial cells, J Urol, 160, 2381, 10.1016/S0022-5347(01)62196-7 Verhagen, 1992, Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer, Cancer Research, 52, 6182 Meeker, 2002, Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis, Cancer Res, 62, 6405 van Leenders, 2003, Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy, Am J Pathol, 162, 1529, 10.1016/S0002-9440(10)64286-1 De Marzo, 2007, Inflammation in prostate carcinogenesis, Nat Rev Cancer, 7, 256, 10.1038/nrc2090 Meissner, 2007, Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells, Nat Biotechnol, 25, 1177, 10.1038/nbt1335 Wong, 2008, Module map of stem cell genes guides creation of epithelial cancer stem cells, Cell Stem Cell, 2, 333, 10.1016/j.stem.2008.02.009